PPI overcomes gefitinib resistance in NSCLC cells by lowering cell viability and triggering death via inhibiting the STAT3 signaling pathway and downregulating MALAT long non-coding RNA [53]. The gene discussed is STAT3; the disease is non-small cell lung carcinoma.